YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
about
Apatinib for molecular targeted therapy in tumorGastric Cancer: New Drugs - New StrategiesMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.Clinical advances in the development of novel VEGFR2 inhibitors.Successful treatment of advanced malignant fibrous histiocytoma of the right forearm with apatinib: a case reportProgression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer.A Case Report of Gastrointestinal Hemorrhage and Perforation During Apatinib Treatment of Gastric CancerApatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease.DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.Molecular targeted therapy for advanced gastric cancerThe Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of LiteratureTherapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage.Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma.Significant partial response of metastatic intra-abdominal and pelvic round cell liposarcoma to a small-molecule VEGFR-2 tyrosine kinase inhibitor apatinib: A case reportThe progress of targeted therapy in advanced gastric cancerDKK4 enhances resistance to chemotherapeutics 5-Fu and YN968D1 in colorectal cancer cells.Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.Novel targeted agents for gastric cancer.Molecular targeted agents for gastric cancer: a step forward towards personalized therapy.Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.Clinical management of advanced gastric cancer: the role of new molecular drugs.Apatinib for the treatment of gastric cancer.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.Angiogenesis inhibitors in gastric and gastroesophageal junction cancer.Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Novel anti-angiogenic therapeutic strategies in colorectal cancer.Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review.The changing landscape of clinical trial and approval processes in China.The effect of apatinib in the treatment of metastatic renal cell carcinoma: a case report and review of the literature.Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer.High-mobility group box-1 contributes tumor angiogenesis under interleukin-8 mediation during gastric cancer progression.Advanced alveolar soft part sarcoma responds to apatinib.Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinomaSuccessful treatment of angiosarcoma of the scalp with apatinib: a case report.Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature reviewApatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case reportEfficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China.
P2860
Q26775828-92271E1B-988E-423C-96FB-7C2559FC55D1Q27028079-1CD66E52-457B-408D-BC43-DA77E1A541D7Q33413742-706BD165-4AA1-4510-9610-736E5A68F947Q34658366-B583013C-19A0-4689-B77C-D39B1359F323Q34675903-6C22B091-8D7E-441F-BA8C-C11110F433BAQ35541950-BD7148CA-7D5C-4217-927F-9D0A8C30B01EQ36195933-6EC9AD07-CCF8-4909-9C27-6D842BE35F4EQ36234315-82AE5EA8-59A3-4E01-9D72-81AD9B44121EQ36644256-66AB144D-36F3-49E9-B752-08D3CC44A13AQ36705689-1223094A-F339-4308-8F9E-D5B5F6B42761Q36993067-F9215FE2-608F-4013-B727-99E3E922EC3EQ37082827-B96471AB-1EFE-418F-9398-C394893F3CF8Q37086246-135CAC04-A73D-4572-8731-6203D80CAB0EQ37164989-7AD139F0-ACC0-4336-983A-AF680225FB73Q37427269-612ADBD8-0775-41AD-A4CD-4E27902BEA65Q37701103-11D5CCBA-8116-4E84-B15F-D8F30240376EQ37705643-B1AFB5BF-0265-4664-9629-5B326B8183FEQ37707033-059BF265-5C17-4423-A6E7-152806B0A312Q38019657-60965D9C-DE5B-4CA1-9261-825EE4CC5843Q38161727-92DF524A-8FC9-42DF-8C03-EA338E72AA3CQ38166329-A625E2CA-CFA1-461F-85B5-2F3B70BA42A1Q38263841-B5527B76-99C4-483B-864F-1377A06528D4Q38270899-C326966F-37E4-4AF4-B0AD-0922790091CDQ38286128-E259E3F1-4CAC-490F-8692-6E9927C2B2C1Q38578404-DC66CAFC-2097-4E9E-BAB6-1FCE215CDBAFQ38635603-25180FD9-D6E6-4AA2-BA50-F1618CD8F632Q38759141-47AB2671-1DD1-4D51-82F8-A2DDB746A8BEQ38964908-F7AA8B34-9553-40F5-B1BB-C40984A2B0A8Q39067386-858AB718-59E8-40B7-9DAF-30CEA8F31BC5Q39134733-CF168E55-534F-4F54-A88C-C8A2918DE0F9Q39455675-D1313AEE-E6FF-4553-AE83-7552EF611C66Q39630965-CCF1DFC6-E09C-443A-8577-5DFBE2EFA371Q41091965-64F712EA-0C80-4934-B55D-D1C9EF24E473Q41248552-A771C2B2-A7E1-4D24-AB4E-C0710DCD6298Q41473058-06815638-089D-4CCB-9269-A0837748649FQ41592916-9CCE6634-F683-4B76-842D-2ACB13E9E249Q41753175-4224BFD9-476E-4595-B067-8C9C99B0D6AAQ41915464-192FE809-14E2-4396-81B9-B88D4F9EEAA9Q42289797-088D3182-A749-4EC6-825E-0D888E1BE7D3Q42362795-DB43EA35-3DBD-43AD-9228-2EB7B527C713
P2860
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@en
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@nl
type
label
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@en
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@nl
prefLabel
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@en
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@nl
P2093
P2860
P1433
P1476
YN968D1 is a novel and selecti ...... activity in vitro and in vivo.
@en
P2093
Chengying Xie
Fangfang Lü
Haitian Quan
Liguang Lou
Yongping Xu
P2860
P304
P356
10.1111/J.1349-7006.2011.01939.X
P577
2011-05-09T00:00:00Z